## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.6% below STRENGTH zone (4.0-10.0%); PEG 1.55 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-11.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($679.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Jim Cramer on Regeneron: “They’re Doing a Lot of Good Stuff, I Lost Sight of It, I Shouldn’t Have”**
- Source: Insider Monkey | 20251204T000400 | Neutral | Relevance: 100%
- Jim Cramer commented on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), acknowledging that he "lost sight of" the company's positive developments despite its significant stock momentum. He shared that he should have been recommending Regeneron and Amgen, highlighting the strong performance of both companies. The article mentions Regeneron's focus on various medical conditions and contrasts its investment potential with more promising AI stocks.

**2. Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny**
- Source: Markets Financial Content | 20251203T185100 | Somewhat-Bearish | Relevance: 100%
- Morgan Stanley has downgraded Regeneron Pharmaceuticals (REGN) to "Equal-Weight" from "Overweight," maintaining a price target of $767.00. The downgrade reflects a belief that the stock is now fairly valued with limited upside, following strong performance and increased scrutiny on its pipeline diversity due to impending patent expirations for key drugs Eylea and Dupixent. This move highlights the pharmaceutical industry's broader trend of focusing on sustainable growth beyond blockbuster products and the need for companies to strategically diversify their pipelines.

**3. Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron**
- Source: ts2.tech | 20251203T183732 | Somewhat-Bullish | Relevance: 100%
- Regeneron Pharmaceuticals (REGN) is navigating a complex period marked by a Morgan Stanley downgrade from Overweight to Equal Weight, despite several positive developments. These include a key U.S. approval for Eylea HD in retinal vein occlusion, an aggressive move into gene editing with Tessera Therapeutics, and strong performance from Dupixent and Libtayo. The company is also investing heavily in R&D and manufacturing capacity, suggesting a transition from a "complex biotech" to a "mature cash machine" with significant pipeline potential, though risks like Eylea competition and manufacturing hurdles remain.

**4. Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors**
- Source: MarketWatch | 20251203T164200 | Bearish | Relevance: 100%
- Regeneron Pharmaceuticals Inc. (REGN) shares fell by 2.47% to $723.67 on Wednesday, despite a positive trading session for the broader market. This marked the fifth consecutive day of losses for the stock. The S&P 500 Index and Dow Jones Industrial Average both saw gains on the same day.

**5. Regeneron, Tessera to advance gene editing therapy for AATD: Deals Report**
- Source: BioCentury | 20251202T215500 | Bullish | Relevance: 100%
- Tessera Therapeutics has secured a $150 million deal with Regeneron Pharmaceuticals to advance its gene editing therapy, TSRA-196, for alpha-1 antitrypsin deficiency (AATD). The collaboration involves Tessera leading the first-in-human program and Regeneron overseeing later-stage development, with both companies agreeing to split costs and profits equally. Tessera is expected to submit an IND for the program by year-end.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |
| 2025-12-03 | Morgan Stanley | $767 | $767 | 0% |
| 2025-11-24 | Scotiabank | $770 | $650 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Morgan Stanley | down | Equal-Weight |
| 2025-11-24 | Scotiabank | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 9 ($97.67M) |
| Sells | 15 ($32.83M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-11.4% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $33M sold (15 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 5 raises (avg +17%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.55 elevated, pricing in significant growth expectations. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (5 raises, avg +17%). Insider buying signal ($97.7M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $83.2B |
| Beta | 0.37 |
| 52W Range | $476.49 - $792.77 |
| Short Interest | 2.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.55 |
| Forward P/E | 18.8 |
| Current P/E | 16.7 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 9.9% to -1.6% (-11.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-5.17), momentum weakening. RSI neutral at 56. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.55% (CS: 38) | Neutral |
| RSI_14 | 56.1 | Neutral |
| MACD Histogram | -5.17 | Bearish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.124x | Above |
| vs SMA200 | 1.207x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $722.80
- **Stop Loss:** $679.00 (6.1% risk)
- **Target:** $766.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 11
- **Position Value:** $7,950.80
- **Portfolio %:** 7.95%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*